Altamira Therapeutics Ltd...
(CYTO)
undefined
undefined%
At close: undefined
0.43
-2.14%
After-hours Dec 13, 2024, 03:20 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue,
expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
Revenue | - | 305.62K | 63.88K | 174.47K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | - | - |
Cost of Revenue | - | 1.44M | 2.24M | - | - | - | - | - | - | - | - | - |
Gross Profit | - | -1.14M | -2.18M | 174.47K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | - | - |
Operating Income | -5.92M | -26.13M | -17.10M | -5.28M | -7.26M | -10.95M | -24.36M | -30.22M | -30.88M | -22.19M | -14.62M | -4.61M |
Interest Income | 730.20K | 969.00 | 3.22K | 258.00 | 17.88K | - | 53.57K | 67.56K | 37.00K | 52.13K | 74.04K | 5.83K |
Pretax Income | -7.27M | -26.54M | -17.37M | -8.22M | -6.83M | -11.33M | -24.43M | -30.79M | -29.70M | -18.18M | -14.70M | -4.60M |
Net Income | -7.27M | -26.53M | -17.39M | -8.20M | -6.63M | -11.50M | -24.41M | -30.66M | -29.70M | -18.18M | -15.00M | -4.60M |
Selling & General & Admin | 3.12M | 5.90M | 6.39M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
Research & Development | 3.04M | 19.68M | 8.94M | 2.86M | 3.33M | 6.69M | 19.21M | 24.78M | 26.54M | 17.70M | 13.25M | 3.99M |
Other Expenses | - | -586.73K | -409.93K | - | - | 215.72K | 87.59K | 34.05K | 62.20K | 73.43K | 49.42K | 34.28K |
Operating Expenses | 6.54M | 24.99M | 14.92M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
Interest Expense | - | 911.87K | 189.69K | 135.15K | 28.63K | 1.07M | 1.64M | 828.55K | 8.00K | 49.63K | 50.18K | - |
Selling & Marketing Expenses | 15.35K | 2.38M | 1.50M | 95.66K | 113.96K | 43.82K | 199.48K | 45.65K | 72.56K | 237.72K | 479.03K | 86.23K |
Cost & Expenses | 6.54M | 26.44M | 17.16M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
Income Tax | - | -10.33K | 21.62K | -21.28K | -193.84K | 162.18K | -17.77K | -131.06K | -84.78K | -892.18K | 305.75K | - |
Shares Outstanding (Basic) | 491.00K | 45.54K | 33.12K | 15.04K | 14.54K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
Shares Outstanding (Diluted) | 491.26K | 45.54K | 33.12K | 15.04K | 14.54K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
EPS (Basic) | -14.81 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
EPS (Diluted) | -14.8 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
EBITDA | -1.35M | -17.64M | -6.72M | -5.26M | -7.24M | -10.95M | -24.31M | -30.06M | -30.84M | -22.19M | -14.51M | -4.60M |
Depreciation & Amortization | 5.92M | 118.89K | 76.36K | 20.04K | 30.82K | 72.71K | 122.78K | 97.60K | 92.78K | 73.98K | 37.52K | 9.24K |